Board Meeting Details
The Board of Directors meeting was held on October 14, 2026 at the Registered Office of the Company from 03:00 PM to 04:00 PM. The Board approved the unaudited financial results for the half year and quarter ended September 30, 2026, along with the Limited Review Report issued by the Statutory Auditors.
Standalone Financial Results (₹ in Lakhs)
Quarterly Performance (Q2 FY2026 vs Q2 FY2025)
- Total Revenue: ₹9.18 lakh (vs ₹8.91 lakh in Q2 FY2025)
- Total Expenses: ₹5.93 lakh (vs ₹2.27 lakh in Q2 FY2025)
- Profit before tax: ₹3.38 lakh (vs ₹6.64 lakh in Q2 FY2025)
- Tax Expense: ₹0.43 lakh deferred tax (vs ₹0.00 in Q2 FY2025)
- Profit after tax: ₹0.00 lakh (vs not clearly stated in Q2 FY2025)
- Other Comprehensive Income: ₹16.27 lakh gain on fair valuation of financial assets
- Total Comprehensive Income: ₹16.27 lakh
- Basic EPS: ₹0.00 (not annualized)
Half Yearly Performance (H1 FY2026 vs H1 FY2025)
- Total Revenue: ₹18.09 lakh (vs ₹105.74 lakh in H1 FY2025)
- Total Expenses: ₹8.20 lakh (vs ₹14.54 lakh in H1 FY2025)
- Profit before tax: ₹9.89 lakh (vs ₹91.20 lakh in H1 FY2025)
- Tax Expense: ₹12.48 lakh deferred tax (vs ₹22.95 lakh in H1 FY2025)
- Profit after tax: ₹5.42 lakh (vs ₹62.25 lakh in H1 FY2025)
- Other Comprehensive Income: ₹48.01 lakh
- Total Comprehensive Income: ₹54.20 lakh
- Basic EPS: ₹0.03 (not annualized)
Year-ended Comparison (FY2026 H1 vs FY2025 Full Year)
- FY2025 Full Year Audited Revenue: ₹123.52 lakh
- FY2025 Full Year Audited Profit after tax: ₹155.55 lakh
Standalone Balance Sheet (as at September 30, 2026)
- Total Assets: ₹2534.21 lakh (vs ₹2739.26 lakh as at March 31, 2026)
- Non-current Assets: ₹2389.18 lakh (Investments: ₹2235 lakh, Loans: ₹104.77 lakh, Deferred tax assets: ₹49.41 lakh)
- Current Assets: ₹145.03 lakh (Trade receivables: ₹110.89 lakh, Cash & cash equivalents: ₹30.31 lakh, Other current assets: ₹3.80 lakh)
- Equity: ₹2527.21 lakh (Share capital: ₹1397.02 lakh, Other equity: ₹1130.19 lakh)
- Current Liabilities: ₹6.99 lakh (Trade payables)
- Paid-up Equity Share Capital: ₹1397.02 lakh (Face value ₹10 each)
Standalone Cash Flow Statement (Year ended September 30, 2026)
- Net cash used in operating activities: ₹(224.89) lakh
- Net cash from investing activities: ₹162.28 lakh
- Net cash from financing activities: ₹36.08 lakh
- Net decrease in cash: ₹(26.53) lakh
- Cash equivalents at beginning: ₹56.85 lakh
- Cash equivalents at end: ₹30.31 lakh
Consolidated Financial Results (₹ in Lakhs)
Quarterly Performance (Q2 FY2026)
- Total Revenue: ₹9.18 lakh
- Total Expenses: ₹11.70 lakh
- Loss before tax: ₹(0.99) lakh
- Tax Expense: ₹0.43 lakh deferred tax
- Loss after tax: ₹(9.06) lakh
- Other Comprehensive Income: ₹16.27 lakh
- Total Comprehensive Income: ₹9.06 lakh
- Basic EPS: ₹(0.06) (not annualized)
Half Yearly Performance (H1 FY2026)
- Total Revenue: ₹18.09 lakh
- Total Expenses: ₹8.20 lakh
- Profit before tax: ₹3.65 lakh
- Tax Expense: ₹12.45 lakh deferred tax
- Profit after tax: ₹39.18 lakh
- Other Comprehensive Income: ₹48.01 lakh
- Total Comprehensive Income: ₹39.18 lakh
- Basic EPS: ₹0.53 (not annualized)
Consolidated Balance Sheet Highlights
- Total Assets: ₹3081.30 lakh (significant increase from ₹2739.26 lakh)
- Borrowings: ₹552.24 lakh (vs ₹0.00 lakh previously)
Auditor's Limited Review Report
Sarang Shivajirao Chavan and Associates (FRN: 159649W) conducted limited review of both standalone and consolidated financial results as per Standard on Review Engagements (SRE) 2410. The review provides moderate assurance that the statements are free from material misstatement. No qualifications were reported in the limited review.
Compliance and Accounting Standards
- Financial results prepared in compliance with Indian Accounting Standards (Ind AS)
- Prepared in accordance with Ind AS 34 - Interim Financial Reporting
- Format modified as per SEBI circular dated July 5, 2016
- Company has one reportable primary pharmaceutical business segment as per IND AS 108
- Previous period figures have been regrouped, reclassified and restated for comparability